[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"right-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:right-heart-failure":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,71,98,127,155,182,204,228],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100473856","phase-2-inhaled-milrinone-and-epoprostenol-for-the-prevention-of-difficult-cardiac-pulmonary-bypass-separation-100473856",false,"NCT05450328","Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation","Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial","MILAN","Inclusion Criteria:\n\n\\- Only patients undergoing cardiac surgery with CPB and aged 18 years and older will be included in this study.\n\nExclusion Criteria:\n\n* The presence of congenital cardiomyopathy, which the correction is the primary objective of the proposed surgery. For example, a patient who requires surgery for atrial septal defect closure only would not be eligible for the study. On the other hand, a patient who undergoes this same surgery in addition to a valve replacement, for example, would be eligible to participate in the study.\n* Heart transplant or ventricular assist device surgery\n* Urgent surgery including hemodynamic instability requiring vasopressor agents upon arrival in the operating room\n* A contraindication to transesophageal ultrasound monitoring or the presence of an unstable cervical spine.\n* Presence of a contraindication related to Epoprostenol or Milrinone administration such as a documented left ventricular or right ventricular outflow tract obstruction, a severe unaddressed aortic stenosis, or a documented allergy to either of these two molecules.",true,"ALL","18 Years",{"count":21,"type":22},141,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","In cardiac surgery, the presence of pulmonary hypertension (PH) is a prognostic factor associated with increased mortality and morbidity. In this context, one of the main causes of PH is related to reperfusion ischemia during weaning from extracorporeal circulation (CPB). One of the consequences of PH is right ventricular dysfunction. During weaning from CPB, the development of a right ventricular dysfunction is associated with increased requirements for vasopressor and inotropic agents, duration of mechanical ventilation, prolonged intensive care and hospital stay, and increased mortality compared with patients with left ventricular (LV) dysfunction. The management of patients with PH with or without right ventricular (RV) dysfunction relies on several strategies such as the administration of intravenous and inhaled agents, or mechanical ventricular support. Among those agents, the administration of inotropes or pulmonary vasodilators such as epoprostenol, milrinone and nitric oxide are among the most widely used treatments recommended by the Canadian Cardiovascular Society. At the Montreal Heart Institute, inhaled epoprostenol and milrinone are routinely administered to patients with PH or LV dysfunction in the perioperative setting. Despite the frequent use of inhaled epoprostenol and milrinone, Health Canada has not yet approved the use of these molecules.\n\nThe primary objective of this multicenter, double-blind, randomized clinical trial is to evaluate the clinical efficacy of the combined administration of inhaled epoprostenol and milrinone in a cardiac surgery setting. This trial will compare the clinical outcome of 71 patients who will receive inhaled epoprostenol and milrinone before the start of bypass surgery to 71 patients who will receive a placebo before the start of the CPB. The primary clinical outcome is the proportion of patients with an \"unsuccessful\" CPB weaning defined by the use of an inotrope +\u002F- vasopressor agent or the use of mechanical circulatory support or a return to bypass grafting for hemodynamic reasons.\n\nThis clinical trial will evaluate the clinical efficacy of the combination of inhaled agents in a cardiac surgery setting. Therefore, if the results of this study are positive, the combination of inhaled epoprostenol and milrinone will optimize the management of patients with pulmonary hypertension with or without a right ventricular dysfunction.",[28,29],"Right Heart Failure","Right Ventricular Dysfunction",[31,29,32,33],"Cardiac Surgery","Cardiopulmonary Bypass","Inhaled Therapy","RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2025-12-10",{"date":42,"type":22},"2028-12-01",{"name":44,"class":45},"Montreal Heart Institute","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100520208","phase-2-repurposing-valsartan-may-protect-against-pulmonary-hypertension-100520208","NCT06053580","Repurposing Valsartan May Protect Against Pulmonary Hypertension","REVAMP-PH","Inclusion Criteria:\n\n1. Male or female, age 18 to 80\n2. WHO Group 1 Pulmonary Arterial Hypertension\n3. NYHA Functional Class II, III, or IV at screening (Appendix 2 for Functional Class Decision Aid)\n4. Right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥25 mmHg, occlusion pressure of ≤15 mmHg, and resistance ≥ 3 wood units\n5. Participants with a right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥ 25 mmHg and occlusion pressure of 15 - 20 mmHg will be considered for inclusion if the pulmonary vascular resistance ≥ 9 wood units and they are being treated with pulmonary arterial hypertension specific therapy\n6. Able to walk with\u002Fwithout a walking aid for a distance of at least 50 meters\n\nExclusion Criteria:\n\n1. Pregnant or lactating\n2. Non-group 1 pulmonary hypertension or veno-occlusive disease\n3. History of interstitial lung disease, unless subject has collagen vascular disease and has pulmonary function testing conducted within 12 months demonstrating a total lung capacity or vital capacity of ≥ 60 %\n4. Has received or will receive an investigational drug, device, or study within 30 days or during the course of study\n5. ACE-inhibitor, ARB or ARNI use within 30 days of randomization.\n6. Left sided myocardial disease as evidenced by left ventricular ejection fraction \\\u003C 40%\n7. Any other clinically significant illness or abnormal laboratory values (measured during the Screening period) that, in the opinion of the Investigator, might put the subject at risk of harm during the study or might adversely affect the interpretation of the study data\n8. Anticipated survival less than 1 year due to concomitant disease\n9. Allergy or angioedema with ACE-inhibitor use\n10. Potassium \\>5mEq\u002FL or sCr \\>2mg\u002FdL at screening\n11. SBP \\\u003C90mmHg at screening","80 Years",{"count":56,"type":22},60,[25],"This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.",[60,28,29,61],"Pulmonary Arterial Hypertension","Pulmonary Vascular Disorder","2026-04-30",{"date":64,"type":38},"2026-05-04",{"date":66,"type":38},"2024-02-28",{"date":68,"type":22},"2027-07-01",{"name":70,"class":45},"University of Washington",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100629084","accelerated-lbbp-for-patients-with-rhf-and-severe-tr-100629084","NCT07470047","Accelerated LBBP for Patients With RHF and Severe TR","Accelerated Left Branch Bundle Pacing in the Treatment of Right Heart Failure With Severe Tricuspid Regurgitation: A Prospective, Multicenter, Single-Arm Target Value Clinical Trial","ARCP","Inclusion Criteria:\n\n1. Mean resting heart rate ≤ 65 beats\u002Fmin (based on a resting electrocardiogram).\n2. Clinically confirmed right-sided heart failure, requiring ≥2 diuretic units to fully control edema, or having persistent grade ≥1 edema despite diuretic therapy.\n\n   Diuretic unit definition: expressed as the number of daily doses at the standard oral dose. For example, the standard units for furosemide, torasemide, and spironolactone are 20 mg\u002Fday, 10 mg\u002Fday, and 20 mg\u002Fday, respectively. If a patient takes furosemide 20 mg twice daily and spironolactone 20 mg once daily, the total diuretic units equal 3.\n3. Echocardiography shows severe or greater tricuspid regurgitation.\n4. With\u002Fwithout an indication for permanent pacemaker implantation.\n5. Is able to understand the purpose of the trial, voluntarily participates and signs written informed consent, and is willing to complete follow-up visits as required by the protocol.\n\nExclusion Criteria:\n\n1. Mean pulmonary artery pressure (mPAP) \\> 35 mmHg measured by right heart catheterization at a pacing rate of 60 bpm.\n2. Left ventricular ejection fraction (LVEF) \\\u003C 50% or left ventricular end-diastolic diameter (LVEDD) \\> 56 mm as measured by echocardiography.\n3. Prior implantation of a cardiac pacemaker.\n4. Moderate or greater left-sided valvular regurgitation or stenosis.\n5. Current use of heart rate-lowering medications, such as beta-blockers, digoxin, ivabradine, etc.\n6. Untreated hypothyroidism.\n7. Participation in another drug or medical device clinical trial that has not yet been completed.\n8. Deemed unsuitable for participation in this clinical trial by the investigator.",{"count":80,"type":22},24,[82],"NA","This study is a prospective, single-arm, target value clinical trial. We plan to prospectively enroll and follow 24 patients across three centers nationwide who have a low baseline heart rate (HR ≤ 60 bpm), meet the indication for permanent pacemaker implantation, and have right-sided heart failure with severe or greater tricuspid regurgitation. All patients will undergo pacemaker implantation using left bundle branch pacing (LBBP), and the pacing rate will be uniformly increased to 90 bpm (reduced to 80-85 bpm in case of intolerance). Patients will be followed for 6 months to evaluate the effects of heart-rate increase on hemodynamics, heart failure symptoms, and physical function in patients with right-sided heart failure.",[28],[86],"right heart failure, left branch bundle pacing, tricuspid regurgitation","NOT_YET_RECRUITING","2026-03-12",{"date":90,"type":38},"2026-03-13",{"date":92,"type":22},"2026-03-10",{"date":94,"type":22},"2027-12-31",{"name":96,"class":45},"Shanghai Zhongshan Hospital",3,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":106,"targetDuration":108,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100627608","incidence-and-evolution-of-heart-lung-interaction-in-acute-respiratory-distress-syndrome-100627608","NCT07450846","Incidence and Evolution of Heart-lung Interaction in Acute Respiratory Distress Syndrome","Incidence and Evolution of Heart-lung Interaction in Acute Respiratory Distress Syndrome: the IVOLIA Study","IVOLIA","Inclusion Criteria:\n\n* Age ≥18 years old\n* Hospitalization in intensive care undergoing mechanical ventilation\n* Presence of ARDS according to the current consensus definition (Berlin definition)\n* Performance of at least one echocardiography during the first 24 hours of treatment, between the 2nd and 3rd day, between the 5th and 7th day, and within 48 hours of extubation\n\nExclusion Criteria:\n\nPregnancy Poor echogenicity preventing reliable measurement of the dimensions of the right and left ventricles.",{"count":107,"type":22},500,"2 Months","OBSERVATIONAL","Acute respiratory distress syndrome (ARDS) is an inflammatory injury of the lungs caused by various serious illnesses, such as a bacterial or viral lung infection. It is treated by artificial ventilation with the application of positive pressure. Pulmonary injury, coupled with artificial ventilation, can lead to right heart failure which hinders the ejection of blood to the pulmonary circulation. Modern mechanical ventilation modalities have reduced the frequency (\"incidence\") of this right heart failure in acute respiratory distress syndrome. A large-scale study has shown this a few years ago. However, the evolution of right heart failure during artificial ventilation, and the consequences it has on the patient's cardiovascular status are poorly determined. This study is conducted to improve knowledge in this area. In adult patients hospitalized in intensive care presenting acute respiratory distress syndrome, the investigators will collect the data recorded on cardiac ultrasound, doses of cardiovascular drugs as well as variables reflecting hemodynamic status and cell oxygenation. Data will be collected during the course of ARDS and mechanical ventilation, as well as after weaning from artificial ventilation.",[112,28],"Acute Respiratory Distress Syndrome",[114,115,116,117],"ARDS","heart-lung interactions","mechanical ventilation","shock","2026-02-26",{"date":120,"type":38},"2026-03-05",{"date":122,"type":38},"2022-12-22",{"date":124,"type":22},"2028-01",{"name":126,"class":45},"Bicetre Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100519102","humanmachine-interface-what-the-heartmate-3--device-tells-us-about-the-future-100519102","NCT06039176","Human\u002FMachine Interface: What the HeartMate 3 ® Device Tells Us About the Future","Inclusion Criteria:\n\n* 18 years of age or older\n* Scheduled Heartmate 3 ® dLVAD implantation\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Scheduled for dLVAD that is NOT a Heartmate 3 (R) device","100 Years",{"count":135,"type":22},150,"Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing size of the newest generation devices leading to a lessened occurrence of adverse events, bleeding and infection still remain a concern for clinicians, as well as a general lack of predictability towards adverse events in individuals with a dLVAD in place. There is a lack of description in the literature currently, regarding the interface between what the pump data provides and what is seen in clinical practice. There also is little known about the effects of what is provided in the pump data, in correlation to quality-of-life following dLVAD implantation.\n\nTherefore, the purpose of this study is to prospectively analyze normal and abnormal pump data through pump operations such as suction events, low flow alarms as well as other adventitious alarms, PI events and power cable disconnects greater than 20 seconds, from the HeartMate 3 ® dLVAD in order to clinically correlate this data to quality of life, frailty and other various medical conditions and adverse events as defined by the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). This will be achieved through two aims: 1) Evaluate the effectiveness of dLVAD pump operations data on clinical practice application (quality of life, frailty and various medical conditions, and adverse events such as GIB, RHF, infection, hypertension, arrhythmias and stroke); and 2) Evaluate correlations and relationships of longitudinal normal and abnormal dLVAD pump operations data, to demographic and clinical variables. This study is the first study to evaluate HeartMate 3 ® dLVAD pump operations data over time for effectiveness in the clinical practice.",[138,139,140,28,141,142,143,144],"LVAD","Frailty","GI Bleed","Infections","Hypertension","Arrhythmias","Stroke","2025-12-08",{"date":147,"type":38},"2025-12-16",{"date":149,"type":38},"2023-10-27",{"date":151,"type":22},"2026-12-30",{"name":153,"class":45},"International Consortium of Circulatory Assist Clinicians",7,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100559925","phase-2-feasibility-trial-for-a-right-ventricular-failure-platform-trial-100559925","NCT06570473","Feasibility Trial for a Right Ventricular Failure Platform Trial","Feasibility Trial for the Canadian Right Ventricular AdaptiVE (CRAVE) Platform for Therapies Targeting Right Ventricular Failure","CRAVE","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Able to provide informed consent.\n3. Able to comply with all study procedures.\n4. History of RV dysfunction or RHF secondary to any of:\n\n   a. Group 1 PH, pulmonary arterial hypertension b. Group 2 PH, left heart disease with normal left ventricular ejection fraction (LVEF) \\> 50% and a previous RHC demonstrating combined pre and post-capillary PH, defined as: i. mPAP \\>20 mmHg ii. PAWP \\> 15 mmHg iii. PVR\\> 2 WU c. Group 3 PH d. Group 4 PH, chronic thromboembolic PH that is either persistent after pulmonary endarterectomy or inoperable due to distal disease.\n5. Symptomatic with current NYHA Functional Class II-IV\n6. Biomarker and 2D echocardiogram evidence of RV dysfunction within 3 months:\n\n   1. NT-proBNP \\>300 ng\u002FL and qualitative evidence of at least 'mild' RV dysfunction on echocardiography OR NT-proBNP\\\u003C300 ng\u002FL and qualitative evidence of at least moderate RV dysfunction and\u002For dilatation on 2D echocardiogram AND\n   2. A quantitative 2D echocardiogram with evidence of RV dysfunction defined as having both of the following:\n\n   i. TAPSE ≤18 mm ii. RV dilatation (RV diameter \\> 42 mm at the base).\n7. Receiving loop diuretics or mineralocorticoid receptor antagonists for at least 4 weeks.\n8. Access to an iOS or android smart phone or tablet.\n\nExclusion Criteria:\n\n1. Estimated glomerular filtration rate (eGFR) \\\u003C30 ml\u002Fmin.\n2. LVEF \\\u003C 50%\n3. Normal RV size and function\n4. Severe aortic or mitral valvular disease\n5. Moderate or severe hepatic dysfunction (Child-Pugh Class B or C)\n6. Participants requiring augmentation of diuretics or otherwise not meeting definition for clinical stability\n7. Pregnancy or lactation\n8. Unable to provide consent and comply with follow-up visits\n9. Listed for lung, heart or heart\u002Flung transplantation\n10. Myocardial infarction or acute coronary syndrome within 90 days of screening\n11. Enrolled in another interventional trial\n12. Planned cardiac or thoracic surgical intervention in the next 6 months.\n13. Known hypersensitivity to empagliflozin or ranolazine.\n14. Concurrent treatment with:\n\n    * strong inhibitors of Cytochrome P450 3A4 (CYP 3A4), (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, nelfinavir, ritonavir, indinavir, saquinavir and grapefruit juice)\n    * class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide) or class III antiarrhythmics (e.g., sotalol, ibutilide, amiodarone, dronedarone)\n    * inducers of CYP 3A4 (e.g., rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort)\n15. Congenital long QT syndrome or a QTc interval \\>500 ms",{"count":164,"type":22},30,[25],"The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.",[168,29,28],"Pulmonary Hypertension",[168,29,28,170,171],"Empagliflozin","Ranolazine","2025-09-16",{"date":174,"type":38},"2025-09-18",{"date":176,"type":38},"2025-07-15",{"date":178,"type":22},"2026-12",{"name":180,"class":45},"University of Alberta",5,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":46},"100593645","cholate-clearance-in-fontan-and-heart-failure-100593645","NCT07009132","Cholate Clearance in Fontan and Heart Failure","Hepatic Perfusion and Liver Health as Assessed by Dual Cholate Clearance Assay in Fontan-associated Liver Disease (FALD)","Inclusion Criteria:\n\n* Fontan: Adult Fontan patients ≥ 18 years of age who have undergone right heart catheterization within the past 1 year.\n* RHF Controls: non-Fontan adults with two ventricle anatomy with systemic left ventricle, CVP estimate ≥ 8 mmHg and left ventricle (LV) function ≥ 50% by echocardiogram performed within the past 1 year. Can include those with congenital heart disease- repaired or unrepaired.\n* Normal Controls: non-Fontan adults with normal cardiac anatomy, normal biventricular function, \\\u003C moderate tricuspid regurgitation and CVP estimate \\\u003C 5 mmHg by echocardiogram performed within the past 1 year.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Unable to comprehend and\u002For give informed consent\n* Sensitivity to human serum albumin, or its preparations\n* Participants with extensive resection of large segments of the small intestine (short gut) or severe gastroparesis\n* Participants on non-selective beta blockers, angiotensin converting-enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), ursodeoxycholic acid, cholic acid, or other bile acids who are unwilling or unable to delay taking their normal dose the morning of their dual cholate clearance testing.\n* Participants on dietary supplements, bile acid sequestrants, GLP-1 agonists, narcotics, and other medications affecting gastric emptying or intestinal absorption who are unwilling or unable to delay taking or withhold as outlined in the instructions on deviating from the SHUNT test.\n* Contraindication to cardiac MRI\n* For RHF and normal controls: diabetes, chronic liver disease, \\>moderate alcohol use, BMI \\>30, oxygen-dependent, pulmonary hypertension22 on therapy, known porto-pulmonary hypertension",{"count":190,"type":22},75,"The goal of this study is to use the HepQuant dual cholate clearance assay, which has been shown to measure liver function in people with known chronic liver conditions, to assess severity of Fontan-associated liver disease (FALD).\n\nThis study aims to understand the role impaired blood flow to the liver plays in liver function in Fontan patients compared to patients with right heart failure and healthy controls. The study will also determine whether cholate clearance is a good measure to use in this population, and whether it will be able to predict clinical outcomes.\n\nParticipants will undergo a HepQuant dual cholate clearance assay and a cardiac magnetic resonance imaging (MRI) at the beginning of the study, and then data on health status will be collected for 5 years.",[193,28],"Fontan","2025-09-09",{"date":196,"type":38},"2025-09-15",{"date":198,"type":38},"2025-08-04",{"date":200,"type":22},"2031-12",{"name":202,"class":203},"HepQuant, LLC","INDUSTRY",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":211,"targetDuration":213,"studyType":109,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100453061","pforzheim-tricuspid-valve-registry---outcomes-of-percutaneous-tricuspid-valve-repair-100453061","NCT05179616","Pforzheim Tricuspid Valve Registry - Outcomes of Percutaneous Tricuspid Valve Repair","Pforzheim Tricuspid Valve Registry: A Real-world Observational Trial Evaluating Outcomes in Patients Treated With the Abbott TriClip™ Device in Helios Klinikum Pforzheim","Inclusion Criteria:\n\n* Subjects (\\>=18 years age) have severe tricuspid regurgitation and are symptomatic despite medical therapy.\n* Subjects eligible to receive the TriClip™\n* Subjects must provide written informed consent prior to study procedure.\n\nExclusion Criteria:\n\n* Subjects participating in another clinical study that may impact the follow-up or results of this study.",{"count":212,"type":22},200,"12 Months","The Pforzheim Tricuspid Valve Registry study is designed to confirm the safety and performance of the TriClip™ device in a contemporary real-world setting in critically ill patients. The observational trial is a prospective, single arm, open-label, single-center, post market registry.",[216,28,217,218],"Tricuspid Regurgitation","Cardiac Remodeling, Ventricular","Cardiac Remodeling, Atrial","2023-09-20",{"date":221,"type":38},"2023-09-22",{"date":223,"type":38},"2020-11-30",{"date":225,"type":22},"2026-11-30",{"name":227,"class":45},"Helios Klinikum Pforzheim",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":236,"enrollmentInfo":237,"targetDuration":239,"studyType":109,"phases":4,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":252},"100516269","right-ventricular-dysfunction-in-chronic-heart-failure-100516269","NCT06002321","Right Ventricular Dysfunction in Chronic Heart Failure","Right Ventricular Dysfunction in Chronic Heart Failure: Clinical Laboratory and Echocardiographic Characteristics","RIVED-CHF","Inclusion Criteria:\n\n* All patients with a diagnosis of chronic heart failure made according to the recommendations of the ESC guidelines through the simultaneous presence of signs and symptoms of disease associated with BNP and NT proBNP levels \\> 100 and 300 pg\u002Fml respectively which are associated with a modest increase PAPS \\> 30 mmHg with or without right ventricular dilatation.\n\nExclusion Criteria:\n\n* Patients with dyspnea of non-cardiogenic origin, related to systemic respiratory diseases, pulmonary embolism, patients with primary pulmonary hypertension will be excluded.\n* Patients with heart failure linked to primary valvular pathologies or infiltrative pathologies, secondary and on a genetic basis, patients diagnosed with acute heart failure in non-optimized therapy for at least 3 months will also be excluded. - Patients with systemic inflammatory neoplastic diseases, advanced liver and kidney diseases awaiting transplantation will be excluded.","90 Years",{"count":238,"type":22},1000,"36 Months","The goal of this multi center observational prospective study is to analyze the concordance between the signs and symptoms of RHF and echocardiographic features of RVD in patient with heart failure. The main questions it aims to answer are:\n\n1. to assess the incidence of RVH and RVD in each HF subtypes.\n2. to evaluate prognostic impact ( in terms of cardiovascular mortality and HF hospitalization) of different RVD patterns during a mean followup period of 3 years\n3. To investigate the incidence of different RV maladaptation ( isolated RV dilatation, isolated Pulmonary hypertension, combined pattern) in each HF groups and the related outcome.\n\nParticipants will follow by direct check up visit and\u002For virtual visits every 6 months for a mean follow-up period of 3 years.",[242,29,28],"Chronic Heart Failure","2023-08-18",{"date":245,"type":38},"2023-08-21",{"date":247,"type":22},"2023-09-01",{"date":249,"type":22},"2026-09-01",{"name":251,"class":45},"University of Siena",14]